Table 1 Characteristics of the study population (n = 2284)

Demographics

 Age

39.4 ± 12.8

 Sex

  - Female

1950 (85.4%)

  - Male

329 (14.4%)

  - Diverse

5 (0.2%)

Headache characteristics

 Diagnosis

  - Migraine without aura

1082 (47.4%)

  - Migraine with aura

442 (19.3%)

  - Migraine with and without aura

173 (7.6%)

  - Chronic migraine

587 (25.7%)

 Headache days per month^a

12.3 ± 8.2

 Severe headache days per month^a

6.3 ± 5.7

 Acute medication days per month^a

6.7 ± 5.4

 Headache intensity [0–10]^a

5.6 ± 2.0

 Headache duration [years]

19.4 ± 14.0

 MIDAS score [0–279]

39.6 ± 47.1

 Current preventive migraine medication

1215 (53.2%)

Current or previous triptan use

 Current or previous use of any triptan

1606 (70.3%)

 Sumatriptan oral

729 (31.9% / 45.4%^b)

 Sumatriptan nasal

39 (1.7% / 2.4%^b)

 Sumatriptan subcutaneous

70 (3.1% / 4.4%^b)

 Rizatriptan

594 (26.0% / 37.0%^b)

 Naratriptan

483 (21.1% / 30.1%^b)

 Zolmitriptan oral

255 (11.2% / 15.9%^b)

 Zolmitriptan nasal

164 (7.2% / 10.2%^b)

 Eletriptan

116 (5.1% / 7.2%^b)

 Almotriptan

65 (2.8% / 4.0%^b)

 Frovatriptan

37 (1.6% / 2.3%^b)